CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Discover which no annual fee travel credit cards provide the highest rewards. Uncover the best options to enhance your travels.
26,108 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A six-pill prescription that would cost $1,000 in the United States ends up costing just $25 through an international...
A prominent fund has taken a sizable stake in Kirby Corporation, with eyes on a bold earnings target of $6.33 per sha...
Magnite's 2025 earnings outlook centers on growing connected TV demand, platform efficiency, and navigating ad-tech p...
A look at how a $1,000 stake in McDonald’s versus Starbucks would have evolved over the past decade, with today’s mar...
A standout AI infrastructure stock is delivering blistering earnings growth in 2026, reshaping the investing landscap...
A contrarian pick in the under-$10 pile is showing improving margins and debt relief, even as investors overlook it. ...
Alphabet stands out as a durable cash engine blending a near-monopoly ad business with AI-driven cloud gains, offerin...
June 2026 opens with a handful of beaten-down stocks that could roar back as inflation cools and earnings beat expect...
Imagine a SpaceX-scale IPO changing how investors price AI startups. This article breaks down what spacex just bigges...
As excitement around Tesla’s humanoid robot mounts, a robotics ETF provides diversified exposure to the broader autom...
Is Micron stock under a lofty price point worth buying? This article breaks down the key factors, including memory ma...